Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZELAPAR

« Back to Dashboard
Zelapar is a drug marketed by Valeant Pharm Intl and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

The generic ingredient in ZELAPAR is selegiline hydrochloride. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.

Summary for Tradename: ZELAPAR

Suppliers: see list1

Clinical Trials for: ZELAPAR

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

Evaluation of Adhesion and Dermal Tolerability of EMSAM
Status: Completed Condition: Healthy

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly
Status: Completed Condition: Healthy

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
Status: Completed Condition: Major Depressive Disorder

A Pilot Study Assessing EmSam in Bipolar Depression
Status: Terminated Condition: Bipolar Depression

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Status: Completed Condition: Parkinson's Disease

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
Status: Completed Condition: Cognitive Disorders; HIV Infections

A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
Status: Completed Condition: Alzheimer Disease, Healthy Volunteer

Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
Status: Completed Condition: Marijuana Abuse

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
Status: Recruiting Condition: Parkinson's Disease; Erectile Dysfunction

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006RXYes5,648,093<disabled>Y<disabled>
Valeant Pharm Intl
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006RXYes6,423,342<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn